目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T19335 | Gap Junction Protein | ||
Danegaptide Hydrochloride (GAP-134 (Hydrochloride)) 是一种具有口服活性的间隙连接蛋白选择性修饰剂,具有抗心律不齐的作用。 | |||
T68077 | |||
Furnidipine 显著降低了 AoD 和 AF 且在大鼠模型中低剂量给药时有抗心律失常和心脏保护作用。 | |||
T25859 | Apoptosis | ||
Necrostatin-7 (Necrostatin 7) 是一种坏死性凋亡抑制剂,具有心脏保护作用,可抑制 RANK-NFATc1 信号传导并减弱巨噬细胞向破骨细胞的分化。 | |||
T5S0833 | Antioxidant | ||
Astragaloside III 是一种分离自黄芪中的一种天然产物。 | |||
TN1982 | Others | ||
Neoglycyrol 是分离自甘草的根中的化合物。它是由传统专利药通脉养心丸中筛选得到,具有潜在心肌保护作用。 | |||
T6454 | Others NF-κB NOD-like Receptor (NLR) | ||
CORM-3 是一种 CO 释放分子,能够减少 NLRP3炎症小体的激活,可以减弱 NF-κB p65的核异位,减少 ROS 的生成,并提高细胞内谷胱甘肽和超氧化物歧化酶的水平。 | |||
T3885 | Others Monoamine Oxidase | ||
Rosiridin (6'-O-Deacetylrosiridoside C) 能够抑制 MAO A 和 MAO B,有潜在的抑郁症和老年性痴呆作用。它在 10 μM 时对 MAO B 的抑制率为 83.8% (pIC50=5.38)。 | |||
T10874 | Calcium Channel | ||
CP-060 是一种 Ca2+ 拮抗剂,能够抑制 Ca2+ 过载,具有抗氧化、保护心脏的作用。 | |||
T8493 | Phosphorylase | ||
Ingliforib (CP 368296) 是glycogen phosphorylase 抑制剂,能够抑制肝脏、肌肉和大脑的 glycogen phosphorylase ,其IC50值分别为 52,352 和 150 nM,具有心脏保护的作用。 | |||
T37807 | |||
Ryanodine receptor (RyR) inhibitor; stabilizes RyR2 in a closed conformation. Exhibits antiarrhythmic and cardioprotective properties in vivo. Hunt et al (2007) K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem.J. 404 431 PMID:17313373 |Chen et al (2008) Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes. Br.J.Pharmacol. 153 915 PMID:17994112 |Ye et al (2012) Designing calcium release channel inhibitors with enhanced electron donor properties: stabilizing the closed state of ryanodine receptor type 1. Mol.Pharmacol. 81 53 PMID:21989257 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPJ-00734 | KNG1 Protein, Human, Recombinant (His) | Human | Human Cells | ||
Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn’t involved in blood clotting.
|
|||||
TMPY-01606 | Kininogen 1 Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Kininogen-1, also known as high molecular weight kininogen, Williams-Fitzgerald-Flaujeac factor, Alpha-2-thiol proteinase inhibitor, Fitzgerald factor, KNG1, and BDK, is a secreted protein that contains three cystatin domains. Kininogen-1 / KNG1 is a protein from the blood coagulation system as well as the kinin-kallikrein system. It is a protein that adsorbs to the surface of biomaterials that come in contact with blood. Kininogen-1 / KNG1 circulates throughout the blood and quickly adsorbs to the material surfaces. Kininogen-1 / KNG1 is one of the early participants of the intrinsic pathway of coagulation, together with Factor XII (Hageman factor) and prekallikrein. Kininogen-1 / KNG1 is one of the kininogens, a class of proteins. As with many other coagulation proteins, the protein was initially named after the patients in whom deficiency was first observed. When the clinical data were combined, it turned out that all patients had a deficiency of the same protein. Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) which is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
|
|||||
TMPY-01598 | Kininogen 1 Protein, Human, Recombinant (His) | Human | HEK293 | ||
Kininogen-1, also known as high molecular weight kininogen, Williams-Fitzgerald-Flaujeac factor, Alpha-2-thiol proteinase inhibitor, Fitzgerald factor, KNG1, and BDK, is a secreted protein that contains three cystatin domains. Kininogen-1 / KNG1 is a protein from the blood coagulation system as well as the kinin-kallikrein system. It is a protein that adsorbs to the surface of biomaterials that come in contact with blood. Kininogen-1 / KNG1 circulates throughout the blood and quickly adsorbs to the material surfaces. Kininogen-1 / KNG1 is one of the early participants of the intrinsic pathway of coagulation, together with Factor XII (Hageman factor) and prekallikrein. Kininogen-1 / KNG1 is one of the kininogens, a class of proteins. As with many other coagulation proteins, the protein was initially named after the patients in whom deficiency was first observed. When the clinical data were combined, it turned out that all patients had a deficiency of the same protein. Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) which is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
|